WallStSmart

Arxis, Inc. Class A Common Stock (ARXS)vsSpace Exploration Technologies Corp. Class A Common Stock (SPCX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Space Exploration Technologies Corp. Class A Common Stock generates 1056% more annual revenue ($19.30B vs $1.67B). ARXS leads profitability with a 6.2% profit margin vs -45.0%. ARXS earns a higher WallStSmart Score of 38/100 (F).

ARXS

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 4.5Value: 4.0Quality: 7.0
Piotroski: 6/9Altman Z: 1.34

SPCX

Avoid

23

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: 0.17

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARXS2 strengths · Avg: 8.0/10
Operating MarginProfitability
24.2%8/10

Strong operational efficiency at 24.2%

Revenue GrowthGrowth
20.7%8/10

Revenue surging 20.7% year-over-year

SPCX2 strengths · Avg: 9.0/10
Market CapQuality
$1.63T10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
15.4%8/10

15.4% revenue growth

Areas to Watch

ARXS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
6.2%3/10

6.2% margin — thin

P/E RatioValuation
2088.5x2/10

Premium valuation, high expectations priced in

Return on EquityProfitability
-1.6%2/10

ROE of -1.6% — below average capital efficiency

SPCX4 concerns · Avg: 3.3/10
Price/BookValuation
18.9x4/10

Trading at 18.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-11.9%2/10

ROE of -11.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ARXS

The strongest argument for ARXS centers on Operating Margin, Revenue Growth. Revenue growth of 20.7% demonstrates continued momentum.

Bull Case : SPCX

The strongest argument for SPCX centers on Market Cap, Revenue Growth. Revenue growth of 15.4% demonstrates continued momentum.

Bear Case : ARXS

The primary concerns for ARXS are EPS Growth, Profit Margin, P/E Ratio. A P/E of 2088.5x leaves little room for execution misses.

Bear Case : SPCX

The primary concerns for SPCX are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

ARXS is growing revenue faster at 20.7% — sustainability is the question.

ARXS generates stronger free cash flow (25M), providing more financial flexibility.

Monitor AEROSPACE & DEFENSE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ARXS scores higher overall (38/100 vs 23/100) and 20.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arxis, Inc. Class A Common Stock

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.

Space Exploration Technologies Corp. Class A Common Stock

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Space Exploration Technologies Corp. The company is headquartered in Starbase, Texas.

Want to dig deeper into these stocks?